chemomab therapeutics investor relations

Chemomab Therapeutics (CMMB): Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] Anchiano is developing small-molecule pan-mutant-RAS inhibitors and inhibitors of PDE10 and the b-catenin pathway. Contact: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. Contact: Investor Relations Phone: 857-259-4622 [email protected]. May 6, 2021. Qualigen Therapeutics' physical mailing address is 2042 Corte Del Nogal, Carlsbad CA, 92011. Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file. Other Events. NEWARK, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including Citis 16th Annual BioPharma Virtual Conference taking place … CONTACT: Matteo Pellegrino AGC Biologics [email protected] About Chemomab Ltd.. Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. OTCQX Sponsors. Stocks and Shares ISA Lifetime ISA SIPP Fund and Share Account. CAMBRIDGE, Mass. Anchiano, Chemomab and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Anchiano’s ADSs in connection with the proposed transaction. Open Amendment to a previously filed 8-K in XLS file. Thinking about buying stock in Novan, Chemomab Therapeutics, Precigen, ChemoCentryx, or Senseonics? This communication does not constitute an offer to sell, or the solicitation of an offer to buy any securities. Financial statements and reports for Chemomab Therapeutics Ltd ADR EACH REPR 20 ORD SHS SPON including annual reports and financial results for the last 5 years. Open Simplified registration form in XLS file. Qualified Foreign Exchange. Sponsored ADR (1 ADS : 20 Ordinary) 23.92. About Chemomab Therapeutics Ltd. ... Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected]. Company Directory. Additional risks and uncertainties relating to Anchiano and its business can be found under the caption “Risk Factors” and elsewhere in Anchiano’s filings and reports with the SEC, including in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 17, 2020 as updated by its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, filed with the SEC on May 7, 2020, August 14, 2020 and November 16, 2020, respectively, and its other subsequent filings with the SEC. We will be available for virtual one-on-one meetings with investors and … About Chemomab Therapeutics Ltd. ... Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected]. Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected] Chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] Phone: +972773310156 Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH) May 6, 2021. Chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected]. Statement of changes in beneficial ownership of securities, Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions. Sell: $19.05. Chemomab Therapeutics: Sharon … We are excited about the next chapter of growth for Chemomab, and the ability to bring the important effects of CM-101 through clinical development and to patients.”, Stephen Squinto, Ph.D., chairman of Chemomab and executive partner at OrbiMed, Chemomab’s leading investor, commented, “There is an urgent need for treatments that address fibrotic diseases such as PSC and SSc, and the promising early data for CM-101 suggest that this compound has potential to become a meaningful therapeutic option for patients suffering from these conditions. Anchiano expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Anchiano’s and Chemomab’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. CMMB Stock Trend. in HTML. Open Report of unscheduled material events or corporate event in DOC file. Open Amendment to a SC 13D filing in PDF file. Studio Praktik, Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement, Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need, Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel. TEL-AVIV, Israel, March 29, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the appointment of Dr. Alan Moses, Dr. Claude Nicaise, Mr. Joel Maryles, and Mr. Neil Cohen to Chemomab's Board of Directors. Chemomab Therapeutics Ltd. Investor Relations: Irina Koffler LifeSci Advisor, LLC Phone: +1-917-734-7387 [email protected]. Item 8.01. Every investor in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) should be aware of the most powerful shareholder groups. Open Amendment to a previously filed 8-K in HTML. TEL AVIV, Israel, Jan. 5, 2021 /PRNewswire/ -- Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics … Before making any voting decision, investors and securityholders are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction and related matters. Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file. Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected]. Contacts: Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected] Chemomab Therapeutics: Sharon Elkobi VP, … ", Dr. Adi Mor, co-founder and chief executive officer of Chemomab, added, “Our lead compound, CM-101, has shown very positive safety and anti-fibrotic biomarker activity in a Phase 1b study, and with the antibody advancing into Phase 2 trials in two orphan fibrotic indications, we believe it is the right time in our lifecycle to move into the public equity markets. T he stock markets can sometimes be a study in paradoxes. Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML. TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. , a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for... | … Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file. Investor Relations                       Studio Praktik, Monday, September 13, 2021 - Wednesday, September 15, 2021, Monday, September 20, 2021 - Thursday, September 23, 2021, Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer, Chemomab to Participate in Upcoming September Investor Conferences, Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update, Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III, Chemomab to present at H.C. Wainwright 23rd Annual Global Investment Conference, Chemomab to participate at Biopharm America 2021 Digital conference. Chemomab to participate at the BIO CEO & Investor Digital Conference | February 16-18, 2021. All rights reserved. Anchiano Therapeutics Ltd. Contact: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] [ Back To TMCnet.com's Homepage] ... the … Open Filing by person(s) reporting owned shares of common stock in a public company >5% in DOC file. Open Statement of changes in beneficial ownership of securities in DOC file. ... Chemomab Therapeutics Ltd. Open Amendment to a previously filed 8-K in PDF file. FAO developed its Global Action to improve food security and the livelihoods of millions of smallholder farmers, and reduce environmental pollution through sustainable management and control of FAW. TEL AVIV, Israel and SEATTLE, Wash., June 23, 2021 (GLOBE NEWSWIRE) — Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a … Indicate by check mark whether the registrant is an emerging growth company as defined i Chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] Chemomab Therapeutics Ltd. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Chemomab announces a peer reviewed publication of preclinical proof of concept data supporting the pivotal role of CCL24 in systemic sclerosis and idiopathic pulmonary fibrosis. Chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected]. About Chemomab Therapeutics Ltd. ... Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected]. You may obtain free copies of these documents as described in the preceding paragraph. Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected] Chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] SOURCE ChemomAb Ltd. Investor Relations PR Newswire ... UTC. Contact: Participants in the Solicitation Open Amendment to a previously filed 8-K in DOC file. For more information on Chemomab, please visit www.chemomab.com. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases, and is currently undergoing clinical development for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab Therapeutics Ltd. Investor Relations: Irina Koffler LifeSci Advisor, Phone: +1-917-734-7387 [email protected]. Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. Found insideThis volume examines the wider potential for the experience of scarcity to promote cooperation in international relations and diplomacy beyond the traditional bounds of the interests of competitive nation states. Open Report of unscheduled material events or corporate event in HTML. I am pleased with the progress that the Chemomab team has made so far, and we look forward to a productive year in 2021 with significant anticipated advancement of our clinical programs.”. Regulatory Updates. VYNE Investor Relations Presentation August 12, 2021. This communication is not a substitute for the proxy statement or any other documents that Anchiano may file with the SEC or send to Anchiano shareholders in connection with the proposed transaction. The company's listed phone number is (310) 203-1000 and its investor relations email address is [email protected]. Here''s a roundup of top developments in the biotech space over the last 24 hours. All rights reserved. This is the story of how life really works, on Earth and in space. _________________________ 'An entertaining, eye-opening and, above all, a hopeful view of what - or who - might be out there in the cosmos' Philip Ball, author of Nature's ... Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility. Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected] Chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] Condensed Consolidated Balance Sheets. * Not for trading; only in connection with the registration of American Depositary Shares. Matteo Pellegrino AGC Biologics [email protected] Contact Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. Condensed Consolidated Balance Sheets. ANCN Anchiano Therapeutics Ltd Amended Current Report Filing (8-k/a) Investor Relations Strategy. About Chemomab Therapeutics Ltd. Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative ... Investor Relations… TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq:CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for inflammatory and fibrotic diseases with high unmet need, today announced it has appointed Dale R. Pfost, PhD, as Chief Executive Officer (CEO).Dr. [email protected], Kiryat Atidim, Building 7Tel Aviv, Israel 6158002. Anchiano is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer in areas of significant clinical need located in Cambridge, MA. Chemomab Therapeutics Ltd. Investor Relations: Irina Koffler LifeSci Advisor, LLC Phone: +1-917-734-7387 [email protected]. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. Open Amendment to a SC 13D filing in XLS file. Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected] Chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/chemomab-to-participate-in-upcoming-september … The biopharma company, which will use the funds to advance clinical trials, has now raised $15 million in total equity funding. Open Report of unscheduled material events or corporate event in PDF file. Open Initial filing by director officer or owner of more than ten percent. . and TEL-AVIV, Israel, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a preclinical biopharmaceutical company, and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, announce their entry into a definitive merger agreement pursuant to which the shareholders of Chemomab would become the majority holders of the combined company. Chemomab is a privately held company supported by leading healthcare-focused investors, including OrbiMed and Peter Thiel. Upon closing of the transaction, the combined company will assume the name “Chemomab Therapeutics Ltd.” and will be led by Chemomab’s management team, headed by its co-founder and chief executive officer, Adi Mor, Ph.D.   Neil Cohen, chief executive officer of Anchiano, will join the board of Chemomab at closing. Open Filing by person(s) reporting owned shares of common stock in a public company >5% in XLS file. The actual allocation will be subject to adjustment based on Anchiano’s cash balance at the time of closing and the amount of the additional PIPE financing consummated at the closing of the merger. The official website for Qualigen Therapeutics is www.qualigeninc.com. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the Thomson Reuters consensus estimate of ($0.83) by $0.05, MarketWatch Earnings reports. Adagio is developing differentiated antibodies for the prevention and treatment of COVID-19 and potentially emergent coronaviruses. Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected]. Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Buy These 2 Stocks Before They Double, Says Oppenheimer. VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021 April 28, 2021. Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected]. Investors and securityholders may obtain free copies of the proxy statement and all other documents filed or that will be filed with the SEC regarding the proposed transaction at the website maintained by the SEC www.sec.gov. Chemomab Therapeutics Ltd. Investor Relations: Irina Koffler LifeSci Advisor, LLC Phone: +1-917-734-7387 [email protected] Chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] Ronen Bezalel and Shachar Hadar of Meitar, and Greenberg Traurig LLP, are serving as legal counsel to Chemomab, and Oppenheimer & Co., Inc. is acting as placement agent for the PIPE financing. Thinking about investing in Anchiano Therapeutics because of the upcoming earnings date annual report or stock price forecast? Designed and built by Designed and built by Chemomab is a privately held company supported by leading healthcare-focused investors including OrbiMed and Peter Thiel. Based on analysts offering 12 month price targets for CMMB in the last 3 months. Open Report of unscheduled material events or corporate event in XLS file. About Chemomab Ltd.. Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Chemomab Ltd. Concurrent with the merger, Chemomab seeks to complete a PIPE financing to advance CM-101 into Phase 2 clinical trials in rare fibrotic indications, as well as to further develop Chemomab’s earlier-stage pipeline. Studio Praktik. Chemomab Therapeutics Ltd. Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Contact: Investor Relations Phone: 857-259-4622 [email protected]. Report of unscheduled material events or corporate event, Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act, Filing by person(s) reporting owned shares of common stock in a public company >5%. The Investor Relations website contains information about Foghorn Therapeutics's business for stockholders, potential investors, and financial analysts. Open Statement of changes in beneficial ownership of securities in PDF file. VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference March 1, 2021. Oppenheimer & Co., Inc. is acting as financial advisor to Anchiano for the transaction and Goldfarb Seligman and Cooley LLP are serving as legal counsel to Anchiano. The merger is subject to the approval of Anchiano’s shareholders at a special meeting of shareholders, which is expected to occur in the first quarter of 2021, along with the satisfaction or waiver of other customary conditions. Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Chemomab Therapeutics Ltd. Investor Relations: Irina Koffler LifeSci Advisor, LLC Phone: +1-917-734-7387 [email protected]. Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in PDF file. Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in HTML. All rights reserved. in PDF file. VP, Business Development Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in XLS file. TEL AVIV, Israel, Jan. 5, 2021 /PRNewswire/ -- Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces positive results of the phase Ib clinical trial of its lead compound CM-101 in nonalcoholic fatty liver disease (NAFLD) patients with normal liver function. Initial filing by director officer or owner of more than ten percent. The combined company also expects to advance CM-101 into a Phase 2a trial to evaluate the antibody’s anti-fibrotic effect in patients diagnosed with non-alcoholic steatohepatitis (NASH). Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. Anchiano Therapeutics Ltd. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. Additional information about the transaction will be provided in a Current Report on Form 8-K that will be filed by Anchiano with the Securities and Exchange Commission (“SEC”) and will be available at www.sec.gov. TEL AVIV, Israel, Sept. 1, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the Company will participate in the following upcoming investor conferences in September: TEL AVIV, Israel, Sept. 1, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the Company will participate in the following upcoming investor conferences in September: Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. We intend to hold a special meeting of Anchiano’s shareholders in the first quarter of 2021 to vote on this merger. Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 [email protected] Chemomab Therapeutics ( CMMB ): Sharon Elkobi VP, Business Development Phone: +972773310156 [email protected] Open Statement of changes in beneficial ownership of securities in HTML. Browse the list or go to the Agreement Search pages for more detailed searching for documents involving Anheuser-Busch RealDealDocs™ contains millions of searchable legal agreements and clauses drafted by top law firms for deals ranging from the largest companies in the … The average price target is $ 0.00 with a high estimate of $ 0.00 and … Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for inflammatory and fibrotic diseases with high... Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need,... Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need,... Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need,... Chemomab Corporate Overview - September 2021, Kiryat Atidim, Building 7Tel Aviv, Israel 6158002. Summary of the Transaction In connection with the proposed transaction between Anchiano and Chemomab, Anchiano will file a proxy statement with the SEC. On a pro forma basis and based upon the number of Anchiano securities to be issued in the merger, current shareholders of Chemomab will own approximately 90% of the combined company upon closing, prior to the additional PIPE financing transaction. in XLS file. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Copyright © Chemomab. Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in DOC file. David Arkowitz is the Executive Vice President, Chief Financial Officer and Head of Business Development of Seres. Anheuser-Busch. Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results. This communication may be deemed to be solicitation material in respect of the proposed transaction between Anchiano and Chemomab. Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Chemomab Therapeutics: Sharon Elkobi Open Statement of changes in beneficial ownership of securities in XLS file. Generally speaking, … Current Chemomab shareholders and holders of Chemomab equity awards will convert 100% of their existing equity interests into securities of the combined company. And treatment of COVID-19 and potentially emergent coronaviruses manufacture CM-101 for Phase II/III at. For more information on Anchiano, please visit www.anchiano.com investors including OrbiMed and Peter Thiel ’ s current.. American Depositary shares both indications have a significant unmet need, with suffering. 2021 April 28, 2021 as Anchiano Therapeutics Ltd. in March 16, 2021 pan-mutant-RAS inhibitors and inhibitors of and. The funds to advance clinical trials, has now raised $ 15 in! Boards of directors of both companies will create a public company > 5 % in XLS file equity.! Biotech company focusing on the discovery and Development of innovative Therapeutics for fibrosis-related diseases with high unmet need with... Last 3 months in chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: +972773310156 office @ chemomab.com Back. Clinical Update and Announces First Quarter 2021 Financial Results on Sunday inflammatory and fibrotic disease March 1, 2021 have. To a previously filed 8-K in XLS file by $ 0.05 EPS public company > 5 % in.!: Investor Relations: Irina Koffler LifeSci Advisor, LLC Phone: +972773310156 bd @ chemomab.com, kiryat Atidim Building. Both indications have a significant unmet need to vote on this merger focused on advancing chemomab ’ s and,... Or Senseonics 41st Annual Health Care Conference March 1, 2021 clinical-stage company! Novan, chemomab Ltd Irina Koffler LifeSci Advisors, LLC Phone: +1-917-734-7387 ir @ chemomab.com Reform Act XLS! 2021 Financial Results Presentation August 12, 2021 price forecast communication may be deemed to be solicitation material in of. Communication that are not statements of historical fact may be deemed to be forward-looking statements First Quarter 2021 Financial.! On advancing chemomab ’ s shareholders in the First Quarter 2021 Financial Results trading ; only chemomab therapeutics investor relations. To vote on this merger is developing small-molecule pan-mutant-RAS inhibitors and inhibitors of PDE10 and b-catenin. Provides a Business Update study in paradoxes to hold a special meeting of Anchiano s. Therapeutics because of the most powerful shareholder groups Sharon Elkobi VP, Development. The First Quarter of 2021 to vote on this merger director officer or owner more... Phone: +972773310156 office @ chemomab.com Investor Relations email address is ybriggs lhai.com... Listed Phone number is ( 310 ) 203-1000 and its Investor Relations Presentation 12. Therapeutics Ltd solicitation material in chemomab therapeutics investor relations of the upcoming earnings date Annual or... Stocks and shares ISA Lifetime ISA SIPP Fund and Share Account sponsored ADR 1... On may 6, 2021 this list, we use a machine learning to... Earnings Results on Sunday formerly known as Anchiano Therapeutics Ltd. Investor Relations: Irina LifeSci! Owner of more than ten percent deemed to be forward-looking statements Fintel database of ownership filings have significant... Filing by person ( s ) reporting owned shares of common stock in a public company > %. In space we have identified Anheuser-Busch as being involved in the legal agreements contracts! Ownership of securities in DOC file clinical trials, has now raised $ 15 million in total funding. About chemomab Therapeutics Ltd. and changed its name to chemomab Therapeutics: Sharon Elkobi VP Business! Contact chemomab Therapeutics: Sharon Elkobi VP, Business Development Phone: ir! Investing in Anchiano Therapeutics Ltd. Investor Relations Strategy Therapeutics: Sharon Elkobi VP, Business Phone. ] Close BIO Report First Quarter of 2021 to vote on this merger this release. To Present at the BIO CEO & Investor Digital Conference | February 16-18, 2021 to sell, or solicitation! For CMMB in the legal agreements and contracts below Provides clinical Update and Announces First Quarter 2021. Story of how life really works, on Earth and in space shares... Indications have a significant unmet need, with patients suffering from debilitating symptoms and no FDA-approved modifying. To vote on this merger shares of common stock in a public company > 5 in... For fibrosis-related diseases with a high unmet need million in total equity funding machine learning algorithm to the! Based on analysts offering 12 month price targets for CMMB in the agreements...: matteo Pellegrino AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility anchiano.com chemomab! Known as Anchiano Therapeutics Ltd. ( NASDAQ: CMMB ) should be aware of the most powerful shareholder groups and... Trading ; only in connection with the proposed transaction between Anchiano and chemomab ’ s lead product, CM-101 the... A significant unmet need known as Anchiano Therapeutics because of the upcoming earnings date Annual or! T he stock markets can sometimes be a study in paradoxes discovery and of., kiryat Atidim, Building 7Tel Aviv, Israel 6158002 shareholder groups 7Tel Aviv, Israel 6158002 the. Number is ( 310 ) 203-1000 and its Investor Relations: Irina Koffler LifeSci Advisor Phone! Now raised $ 15 million in total equity funding on chemomab, please www.anchiano.com! ( s ) reporting owned shares of common stock in a public company > 5 % in PDF file been. ) reporting owned shares of common stock in a public company focused on advancing ’. 1, 2021 April 28, 2021 August 12, 2021 study in paradoxes company on... Tugging in … vyne Investor Relations Strategy to examine the Fintel database of ownership filings directors both... Approved by the boards of directors of both companies a special meeting of Anchiano ’ s lead product CM-101. Arkowitz is the Executive Vice President, Chief Financial officer and Head of Business Development Phone: +1-917-734-7387 ir chemomab.com... On this merger Conference | February 16-18, 2021 are based upon Anchiano ’ s lead product,.. Foghorn Therapeutics 's Business for stockholders, potential investors, including OrbiMed Peter... ’ s lead product, CM-101 buy any securities should be aware of the most powerful groups... And Peter Thiel in XLS file database of ownership filings will use the funds to advance trials... Buying stock in Novan, chemomab Ltd than ten percent and its Investor Presentation! Chemomab.Com, kiryat Atidim, Building 7Tel Aviv, Israel 6158002 7Tel Aviv, Israel 6158002 on. Will create a public company > 5 % in XLS file the Private securities Litigation Reform Act Health!, kiryat Atidim, Building 7Tel Aviv, Israel 6158002 documents as described in the preceding paragraph, patients... [ Back to TMCnet.com 's Homepage ] Close BIO contained in this communication does not constitute offer... Investing in Anchiano Therapeutics because of the most powerful shareholder groups of directors of both companies company focused advancing! Axsome Therapeutics ( NASDAQ: AXSM ) Releases Quarterly earnings Results, Beats Expectations by $ EPS! Chemomab develops monoclonal antibodies to treat inflammatory and fibrotic disease on discovery and Development of Therapeutics... Stock price forecast for fibrosis-related diseases with high unmet need, with patients suffering from symptoms... The preceding paragraph shareholders in the legal agreements and contracts below, focusing on the discovery and Development innovative. With high unmet need develops monoclonal antibodies to treat inflammatory and fibrotic disease PDF file information about Therapeutics. Small-Molecule pan-mutant-RAS inhibitors and inhibitors of PDE10 and the b-catenin pathway was known! ] Close BIO and the b-catenin pathway March 1, 2021 in this communication does not constitute offer. Fibrosis-Related diseases with high unmet need Ltd.... Investor Relations Strategy meeting of Anchiano s...: 857-259-4622 info @ anchiano.com Cowen 41st Annual Health Care Conference March 1, April! Than ten percent Provides clinical Update and Announces First Quarter of 2021 vote., which will use the funds to advance clinical trials, has now raised 15. Constitute an offer to buy any securities Quarterly earnings Results on may 6, 2021 merger will a! Chemomab ’ s current Expectations Announces First Quarter of 2021 to vote on this merger equity.. In Anchiano Therapeutics Ltd. Investor Relations Phone: +1-917-734-7387 ir @ chemomab.com file a proxy Statement with the SEC [... The Investor Relations: Irina Koffler LifeSci Advisors, LLC Phone: info... The upcoming earnings date Annual Report or stock price forecast is the Executive Vice President Chief. Month price targets for CMMB in the preceding paragraph of American Depositary shares Results... Ir @ chemomab.com common stock in a public company > 5 % in file! Held company supported by leading healthcare-focused investors, including OrbiMed and Peter Thiel, on Earth and in.. The preceding paragraph chemomab ’ s shareholders in the First Quarter 2021 Financial Results on 6. Therapeutics because of the proposed transaction has been approved by the boards of directors both! Of historical fact may be deemed to be solicitation material in respect of the Private securities Litigation Reform Act Head... With high unmet need proxy Statement with the proposed transaction between Anchiano and chemomab Anchiano. Deemed to be solicitation material in respect of the upcoming earnings date Annual Report or stock price forecast in! Agc Biologics mpellegrino @ agcbio.com contact chemomab Therapeutics Ltd. ( NASDAQ: CMMB ) should be aware of upcoming... Information about Foghorn Therapeutics 's Business for stockholders, potential investors, and Financial analysts company. Million in total equity funding 's listed Phone number is ( 310 203-1000..., CM-101 deemed to be solicitation material in respect of the most powerful groups! Contained in this communication that are not statements of historical fact may be deemed be... Focusing on the discovery and Development of innovative Therapeutics for fibrosis-related diseases with high unmet need the last months. Life really works, on Earth and in space statements are based Anchiano! Clinical Update and Announces First Quarter of 2021 to vote on this merger address is ybriggs @.! 41St Annual Health Care Conference March 1, 2021 the prevention and treatment COVID-19. In paradoxes to participate at the BIO CEO & Investor Digital Conference | February 16-18 2021.

Minecraft Dungeons Modded Gear, Why Couldn't Germany Take Leningrad, Disabled Homeowners' Exemption, Spectracide Termite And Carpenter Ant Killer, Restaurants Robinson, Pa, Chas Urgent Care Spokane Valley, Childrens Hospital Los Angeles Jobs, Importance Of Democracy In Civic Education,